Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy

• Published in: Clinical therapeutics Vol. 42; no. 5; pp. 802 - 817
• Main Authors: Tichy, Eszter, Torres, Antoni, Bassetti, Matteo, Kongnakorn, Thitima, Di Virgilio, Roberto, Irani, Paurus, Charbonneau, Claudie
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2020; Elsevier Limited
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents - economics; Anti-Bacterial Agents - therapeutic use; Antibiotics; avibactam; Azabicyclo Compounds - economics; Azabicyclo Compounds - therapeutic use; CAZ-AVI; Ceftazidime; Ceftazidime - economics; Ceftazidime - therapeutic use; Clinical medicine; Clinical trials; Colistin; Cost analysis; Cost-Benefit Analysis; cost-effective analysis; Double-Blind Method; Drug Combinations; Drug dosages; Drug resistance; E coli; Female; Health care; Healthcare-Associated Pneumonia - drug therapy; Healthcare-Associated Pneumonia - economics; hospital-acquired pneumonia; Hospitals; Human subjects; Humans; Internal Medicine; Italy; Male; Medical Education; Meropenem; Meropenem - economics; Meropenem - therapeutic use; Middle Aged; Mortality; Nosocomial infection; Pathogens; Patients; Pneumonia; Ventilator-associated pneumonia; Ventilators; Young Adult; Italy; United States > US; ventilator-associated pneumonia; cost-effective analysis; ceftazidime; CAZ-AVI; hospital-acquired pneumonia; avibactam

Ceftazidime/avibactam (CAZ-AVI) is a fixed-dose combination antibiotic approved in Europe and the United States for patients with hospital-acquired pneumonia, including ventilator-associated pneumonia (HAP/VAP). The economic benefits of a new drug such as CAZ-AVI are required to be assessed against...